March 27 (Reuters) - U.S. regulators have approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with annual sales of more than $3 billion.
Combined clinical trial data showed Tecfidera, formerly known as BG-12, cut the average relapse rate by 49 percent after two years compared to patients taking a placebo.
(Reporting By Toni Clarke in Washington; Editing by Tim Dobbyn)
((toni.clarke@thomsonreuters.com)(202-898-8340)(Reuters
Messaging: toni.clarke.thomsonreuters.com@reuters.net))
Keywords: BIOGEN TECFIDERA/
0 comments:
Post a Comment